目的 探討復(fù)方皂礬丸聯(lián)合琥珀酸亞鐵治療缺鐵性貧血的臨床效果。方法 選取2019年1月—2021年10月海南醫(yī)學(xué)院第一附屬醫(yī)院收治的116例缺鐵性貧血患者，隨機(jī)分成對(duì)照組（58例）和治療組（58例）。對(duì)照組口服琥珀酸亞鐵片，2片/次，2次/d。在對(duì)照組基礎(chǔ)上，治療組飯后口服復(fù)方皂礬丸，8丸/次，3次/d。兩組均連續(xù)治療8周。觀察兩組患者臨床療效，比較治療前后兩組患者主要癥狀評(píng)分，血常規(guī)參數(shù)血紅蛋白（HBG）、平均紅細(xì)胞血紅蛋白量（MCH）、平均紅細(xì)胞體積（MCV）、紅細(xì)胞比容（HCT）水平，鐵代謝參數(shù)血清鐵蛋白（SF）和轉(zhuǎn)鐵蛋白飽和度（TSAT）水平，及血清可溶性轉(zhuǎn)鐵蛋白受體（sTFR）、促紅細(xì)胞生成素（EPO）、一氧化氮（NO）、腫瘤壞死因子-α（TNF-α）和白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，治療組臨床有效率為96.55%，顯著高于對(duì)照組[86.21%，P＜0.05]。治療后，兩組主要癥狀評(píng)分較治療前均顯著減少（P＜0.05），且均以治療組的下降更顯著（P＜0.05）。與治療前對(duì)比，治療后兩組血常規(guī)參數(shù)HGB、MCH、MCV、HCT均顯著增高（P＜0.05），且治療組的改善更顯著（P＜0.05）。治療后，兩組SF水平和TSAT均較治療前顯著升高，而血清sTFR、EPO水平則均顯著降低（P＜0.05），且治療后，治療組SF、TSAT、sTFR和EPO水平均顯著優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組血清NO、TNF-α及IL-6水平均較治療前顯著下降（P＜0.05），且治療后治療組降低作用較對(duì)照組更顯著（P＜0.05）。結(jié)論 復(fù)方皂礬丸聯(lián)合琥珀酸亞鐵治療缺鐵性貧血可獲得確切療效，能明顯緩解患者貧血癥狀，改善血常規(guī)及鐵代謝，并能進(jìn)一步抑制血清NO、TNF-α和IL-6的表達(dá)水平，安全性較高。

Objective To explore the clinical effect of Compound Zaofan Pills combined with ferrous succinate in treatment of iron deficiency anemia. Methods Patients (116 cases) with iron deficiency anemia in the First Affiliated Hospital of Hainan Medical University from January 2019 to October 2021 were randomly divided into control (58 cases) and treatment (58 cases) group. Patients in the control group were po administered with Ferrous Succinate Tablets, 2 tablets/time, twice daily. Patients in the treatment group were po administered with Compound Zaofan Pills after meals on the basis of the control group, 8 pills/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, the main clinical symptom scores, the levels of blood routine indexes HGB, MCH, MCV, HCT, iron metabolism parameters SF and TSAT, and serum NO, TNF-α and IL-6 levels in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.55% (56/58), which was significantly higher than that of the control group[86.21% (50/58), P < 0.05]. After treatment, the scores of main symptoms in two groups were significantly lower than those before treatment (P < 0.05), and the decrease in the treatment group was more significant (P < 0.05). Compared with those before treatment, the blood routine parameters HGB, MCH, MCV and HCT in two groups were significantly increased after treatment, and the improvement in the treatment group was more significant (P < 0.05). After treatment, the levels of SF and TSAT in two groups were significantly higher than those before treatment, while the levels of serum sTFR and EPO were significantly decreased (P < 0.05). After treatment, the levels of SF, TSAT,sTFR and EPO in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the levels of serum NO, TNF-α and IL-6 in two groups were significantly lower than those before treatment (P < 0.05), and the effect of treatment group was more significant than that of control group (P < 0.05). Conclusion Compound Zaofan Pills combined with ferrous succinate in treatment of iron deficiency anemia can obtain definite curative effect, obviously relieve the symptoms of anemia, improve blood routine and iron metabolism, and further inhibit the expression levels of serum NO, TNF- α and IL-6.

R973

吳階平醫(yī)學(xué)基金會(huì)臨床科研專項(xiàng)資助(320.3750.18389)